Publications

Publications 2015

December 31, 2015
  1. Ananworanich J, Prasitsuebsai W, Kerr SJ, Hansudewechakul R, Teeratakulpisarn N, Saisawat K, Ramautarsing R, Achalapong J, Pussadee K, Keadpudsa S, Mackay T, Pankam T, Rodbamrung P, Petdachai W, Chokephaibulkit K, Sohn AH, Phanuphak N. Cervical cytological abnormalities and HPV infection in perinatally HIV-infected adolescents. J Virus Erad. 2015 Jan;1(1):30-37.
  2. Lertdumrongluk K, Thongmee T, Kerr SJ, Theamboonlers A, Poovorawan Y, Rianthavorn P. Diagnostic accuracy of urine heparin binding protein for pediatric acute pyelonephritis. Eur J Pediatr. 2015 Jan;174(1):43-8. doi: 10.1007/s00431-014-2362-y. Epub 2014 Jun 26.
  3. Limpaphayom N, Kerr SJ, Prasongchin P. Idiopathic clubfoot: ten year follow-up after a soft tissue release procedure. Int Orthop. 2015 Jan;39(1):81-6. doi: 10.1007/s00264-014-2526-4. Epub 2014 Sep 18.
  4. Madhavi V, Ana-Sosa-Batiz FE, Jegaskanda S, et al. Antibody-dependent effector functions against HIV decline in subjects on antiretroviral therapy. J Infect Dis. 2015 Feb 15;211(4):529-38. doi: 10.1093/infdis/jiu486. Epub 2014 Aug 28.
  5. Boyd MA, Moore CL, Molina JM, Wood R, Madero JS, Wolff M, Ruxrungtham K, Losso M, Renjifo B, Teppler H, Kelleher AD, Amin J, Emery S, Cooper DA; SECOND-LINE study group. Baseline HIV-1 resistance, virological outcomes, and emergent resistance in the SECOND-LINE trial: an exploratory analysis. Lancet HIV. 2015 Feb;2(2):e42-51. doi: 10.1016/S2352-3018(14)00061-7. Epub 2015 Jan 20.
  6. Winston A, Puls R, Kerr SJ, Duncombe C, Li P, Gill JM, Ramautarsing R, Taylor-Robinson SD, Emery S, Cooper DA; ALTAIR Study Group. Differences in the Direction of Change of Cerebral Function Parameters Are Evident over Three Years in HIV-Infected Individuals Electively Commencing Initial cART. PLoS One. 2015 Feb 27;10(2):e0118608. doi: 10.1371/journal.pone.0118608. eCollection 2015.
  7. Boettiger DC, Nguyen VK, Durier N, Bui HV, Heng Sim BL, Azwa I, Law M, Ruxrungtham K. Efficacy of second-line antiretroviral therapy among people living with HIV/AIDS in Asia: results from the TREAT Asia HIV observational database. J Acquir Immune Defic Syndr. 2015 Feb 1;68(2):186-95. doi: 10.1097/QAI.0000000000000411.
  8. Rongkavilit C, Wang B, Naar-King S, et al. Motivational Interviewing Targeting Risky Sex in HIV-Positive Young Thai Men Who Have Sex with Men. Arch Sex Behav. 2015 Feb;44(2):329-40. doi: 10.1007/s10508-014-0274-6. Epub 2014 Mar 26.
  9. Amin J, Boyd MA, Kumarasamy N, Moore CL, Losso MH, Nwizu CA, Mohapi L, Kerr SJ, Sohn AH, Teppler H, Renjifo B, Molina JM, Emery S, Cooper DA. Raltegravir Non-Inferior to Nucleoside Based Regimens in SECOND-LINE Therapy with Lopinavir/Ritonavir over 96 Weeks: A Randomised Open Label Study for the Treatment Of HIV-1 Infection. PLoS One. 2015 Feb 27;10(2):e0118228. doi: 10.1371/journal.pone.0118228. eCollection 2015.
  10. Mocroft A, Lundgren JD, Ross M, Law M, Reiss P, Kirk O, Smith C, Wentworth D, Neuhaus J, Fux CA, Moranne O, Morlat P, Johnson MA, Ryom L; D:A:D study group; Royal Free Hospital Clinic Cohort; INSIGHT study group; SMART study group; ESPRIT study group. Development and validation of a risk score for chronic kidney disease in HIV infection using prospective cohort data from the D:A:D study. PLoS Med. 2015 Mar 31;12(3):e1001809. doi: 10.1371/journal.pmed.1001809. eCollection 2015 Mar.
  11. Han N, Wright ST, O’Connor CC, Hoy J, Ponnampalavanar S, Grotowski M, Zhao HX, Kamarulzaman A; Australian HIV Observational Database (AHOD); TREAT Asia HIV Observational Database (TAHOD). HIV and aging: insights from the Asia Pacific HIV Observational Database (APHOD). HIV Med. 2015 Mar;16(3):152-60. doi: 10.1111/hiv.12188. Epub 2014 Nov 18.
  12. Bunupuradah T, Hansudewechakul R, Kosalaraksa P, Ngampiyaskul C, Kanjanavanit S, Wongsawat J, Luesomboon W, Sophonphan J, Puthanakit T, Ruxrungtham K, Shearer WT, Ananworanich J. HLA-DRB1454 and predictors of new-onset asthma in HIV-infected Thai children. Clin Immunol. 2015 Mar;157(1):26-9. doi: 10.1016/j.clim.2014.12.006. Epub 2014 Dec 26.
  13. Bunupuradah T, Sricharoenchai S, Hansudewechakul R, Klinbuayaem V, Teeraananchai S, Wittawatmongkol O, Akarathum N, Prasithsirikul W, Ananworanich J; Pediatric PROGRESS Study Team. Risk of first-line antiretroviral therapy failure in HIV-infected Thai children and adolescents. Pediatr Infect Dis J. 2015 Mar;34(3):e58-62. doi: 10.1097/INF.0000000000000584.
  14. Ballif M, Renner L, Claude Dusingize J, Leroy V, Ayaya S, Wools-Kaloustian K, Cortes CP, McGowan CC, Graber C, Mandalakas AM, Mofenson LM, Egger M, Kumara Wati KD, Nallusamy R, Reubenson G, Davies MA, Fenner L; International Epidemiologic Databases to Evaluate AIDS (IeDEA); International Epidemiologic Databases to Evaluate AIDS IeDEA. Tuberculosis in Pediatric Antiretroviral Therapy Programs in Low- and Middle-Income Countries: Diagnosis and Screening Practices. J Pediatric Infect Dis Soc. 2015 Mar;4(1):30-8. doi: 10.1093/jpids/piu020. Epub 2014 Mar 28.
  15. Baker J, Engen N, Huppler Hullsiek K, Stephan C, Jain M, Munderi P, Pett S, Duprez D; International Network for Strategic Initiatives in Global HIV Trials (INSIGHT) START Study Group. Assessment of arterial elasticity among HIV-positive participants with high CD4 cell counts: a substudy of the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial. HIV Med. 2015 Apr;16 Suppl 1:109-18. doi: 10.1111/hiv.12239.
  16. Soliman E, Sharma S, Arastéh K, Wohl D, Achhra A, Tambussi G, O’Connor J, Stein J, Duprez D, Neaton J, Phillips A; International Network for Strategic Initiatives in Global HIV Trials (INSIGHT) START Study Group. Baseline cardiovascular risk in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial. HIV Med. 2015 Apr;16 Suppl 1:46-54. doi: 10.1111/hiv.12233.
  17. Matthews G, Neuhaus J, Bhagani S, Mehta Sh, Vlahakis E, Doroana M, Naggie S, Arenas-Pinto A, Peters L, Rockstroh J; International Network for Strategic Initiatives in Global HIV Trials (INSIGHT) START Study Group. Baseline prevalence and predictors of liver fibrosis among HIV-positive individuals: a substudy of the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial. HIV Med. 2015 Apr;16 Suppl 1:129-36. doi: 10.1111/hiv.12241.
  18. Winston A, Amin J, Clarke A, Else L, Amara A, Owen A, Barber T, Jessen H, Avihingsanon A, Chetchotisakd P, Khoo S, Cooper DA, Emery S, Puls R; ENCORE Cerebrospinal Fluid (CSF) Substudy Team; ENCORE Cerebrospinal Fluid CSF Substudy Team. Cerebrospinal fluid exposure of efavirenz and its major metabolites when dosed at 400 mg and 600 mg once daily: a randomized controlled trial. Clin Infect Dis. 2015 Apr 1;60(7):1026-32. doi: 10.1093/cid/ciu976. Epub 2014 Dec 11.
  19. Ramautarsing RA, Phanuphak N, Chaithongwongwatthana S, Wit FW, Teeratakulpisarn N, Pankam T, Rodbamrung P, Wijgert JH, Lange JM, Phanuphak P, Sahasrabuddhe VV, Kerr S, Ananworanich J. Cervical and anal HPV infection: cytological and histological abnormalities in HIV-infected women in Thailand. J Virus Erad. 2015 Apr 1;1(2):96-102.
  20. Grarup J, Rappoport C, Engen N, Carey C, Hudson F, Denning E, Sharma S, Florence E, Vjecha M; International Network for Strategic Initiatives in Global HIV Trials (INSIGHT) START Study Group. Challenges, successes and patterns of enrolment in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial. HIV Med. 2015 Apr;16 Suppl 1:14-23. doi: 10.1111/hiv.12229.
  21. Law M, Achhra A, Deeks S, Gazzard B, Migueles S, Novak R, Ristola M; International Network for Strategic Initiatives in Global HIV Trials (INSIGHT) START Study Group. Clinical and demographic factors associated with low viral load in early untreated HIV infection in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial. HIV Med. HIV Med. 2015 Apr;16 Suppl 1:37-45. doi: 10.1111/hiv.12232.
  22. Sharma S, Babiker A, Emery S, Gordin F, Lundgren J, Neaton J, Bakowska E, Schechter M, Wiselka M, Wolff M; International Network for Strategic Initiatives in Global HIV Trials (INSIGHT) START Study Group. Demographic and HIV-specific characteristics of participants enrolled in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial. HIV Med. 2015 Apr;16 Suppl 1:30-6. doi: 10.1111/hiv.12231.
  23. Ohata P, Chumchure R, Nanthapisal K, Ruengpanyathip C, Koita P, Phuanglek T, Avihingsanon A,  Puthanakit T, Phanuphak N,  Kerr SJ, Bunupuradah T, Prasitsuebsai W, Kancheva Landolt N, Sudjaritruk T, Sapsirisavat V, Do T, Auchieng C, Ruxrungtham K, Phanuphak P. Ending AIDS and challenges for Asia. Future Virology 2015 Apr; 10(4):341-345.
  24. Kerr SJ, Punyawudho B, Thammajaruk N, Colbers A, Chaiyahong P, Phonphithak S, Sapsirisavat V, Ruxrungtham K, Burger DM, Avihingsanon A. Factors associated with daily tenofovir exposure in Thai subjects taking combination antiretroviral therapy. AIDS Res Hum Retroviruses. 2015 Apr;31(4):368-74. doi: 10.1089/AID.2014.0249. Epub 2014 Dec 17.
  25. Wright E, Grund B, Cysique, Robertson K, Brew B, Collins G, Shlay J, Winston A, Read T, Price R; International Network for Strategic Initiatives in Global HIV Trials (INSIGHT) START Study Group. Factors associated with neurocognitive test performance at baseline: a substudy of the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial. HIV Med. 2015 Apr;16 Suppl 1:97-108. doi: 10.1111/hiv.12238.
  26. Baxter J, Dunn D, White E, Sharma S, Geretti A, Kozal M, Johnson M, Jacoby S, Llibre J, Lundgren J; International Network for Strategic Initiatives in Global HIV Trials (INSIGHT) START Study Group. Global HIV-1 transmitted drug resistance in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial. HIV Med. 2015 Apr;16 Suppl 1:77-87. doi: 10.1111/hiv.12236.
  27. Manosuthi W, Ongwandee S, Bhakeecheep S, Leechawengwongs M, Ruxrungtham K, Phanuphak P, Hiransuthikul N, Ratanasuwan W, Chetchotisakd P, Tantisiriwat W, Kiertiburanakul S,Avihingsanon A, Sukkul A, Anekthananon T; Adults and Adolescents Committee of the Thai National HIV Guidelines Working Group. Guidelines for antiretroviral therapy in HIV-1 infected adults and adolescents 2014, Thailand. AIDS Res Ther. 2015 Apr 24;12:12. doi: 10.1186/s12981-015-0053-z. eCollection 2015.
  28. Achhra A, Mocroft A, Ross M, Ryom L, Lucas G, Furrer H, Neuhaus J, Somboonwit C, Kelly M, Gatell J, Wyatt C; International Network for Strategic Initiatives in Global HIV Trials (INSIGHT) START Study Group. Kidney disease in antiretroviral-naïve HIV-positive adults with high CD4 counts: prevalence and predictors of kidney disease at enrolment in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial. HIV Med. 2015 Apr;16 Suppl 1:55-63. doi: 10.1111/hiv.12234.
  29. Carr A, Grund B, Neuhaus J, Schwartz A, Bernardino J, White D, Badel-Faesen S, Avihingsanon A, Ensrud K, Hoy J; International Network for Strategic Initiatives in Global HIV Trials (INSIGHT) START Study Group. Prevalence of and risk factors for low bone mineral density in untreated HIV infection: a substudy of the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial. HIV Med. 2015 Apr;16 Suppl 1:137-46. doi: 10.1111/hiv.12242.
  30. Kunisaki K, Niewoehner, Collins G, Nixon, Tedaldi E, Akolo C, Kityo C, Klinker H, La Rosa A, Connett J; International Network for Strategic Initiatives in Global HIV Trials (INSIGHT) START Study Group. Pulmonary function in an international sample of HIV-positive, treatment-naïve adults with CD4 counts > 500 cells/μL: a substudy of the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial. HIV Med. 2015 Apr;16 Suppl 1:119-28. doi: 10.1111/hiv.12240.
  31. Lifson A, Grandits G, Gardner E, Wolff M, Pulik P, Williams I, Burman W; International Network for Strategic Initiatives in Global HIV Trials (INSIGHT) START Study Group. Quality of life assessment among HIV-positive persons entering the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial. HIV Med. 2015 Apr;16 Suppl 1:88-96. doi: 10.1111/hiv.12237.
  32. Denning E, Sharma S, Smolskis M, Touloumi G, Walker S, Babiker A, Clewett M, Emanuel E, Florence E, Papadopoulos A, Sánchez A, Tavel J, Grady C; International Network for Strategic Initiatives in Global HIV Trials (INSIGHT) START Study Group. Reported consent processes and demographics: a substudy of the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial. HIV Med. 2015 Apr;16 Suppl 1:24-9. doi: 10.1111/hiv.12230.
  33. Aurpibul L, Puthanakit T. Review of tenofovir use in HIV-infected children. Pediatr Infect Dis J. 2015 Apr;34(4):383-91. doi: 10.1097/INF.0000000000000571.
  34. Rodger A, Lampe F, Grulich A, Fisher M, Friedland G, Phanuphak N, Bogner J, Pereira L, Rietmeijer C, Burman W, Phillips A; International Network for Strategic Initiatives in Global HIV Trials (INSIGHT) START Study Group. Transmission risk behaviour at enrolment in participants in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial. HIV Med. 2015 Apr;16 Suppl 1:64-76. doi: 10.1111/hiv.12235.
  35. INSIGHT Strategic Timing of AntiRetroviral Treatment (START) Study Group, Lundgren J, Babiker A, Gordin F, Emery S, Fätkenheuer G, Molina JM, Wood R, Neaton JD. Why START? Reflections that led to the conduct of this large long-term strategic HIV trial. HIV Med. 2015 Apr;16 Suppl 1:1-9. doi: 10.1111/hiv.12227.
  36. Hayashi K, Ti L, Avihingsanon A, Kaplan K, Suwannawong P, Wood E, Montaner J, Kerr T. Compulsory drug detention exposure is associated with not receiving antiretroviral treatment among people who inject drugs in Bangkok, Thailand. Subst Abuse Treat Prev Policy. 2015 May 6;10:16. doi: 10.1186/s13011-015-0013-6.
  37. Lee MP, Zhou J, Messerschmidt L, Honda M, Ditangco R, Sirisanthana T, Kumarasamy N,Phanuphak P, Chen YM, Zhang F, Saphonn V, Kiertiburanakul S, Lee CK, Pujari S, Choi JY, Kamarulzaman A, Yunihastuti E, Merati TP, Lim PL, Li PC; TREAT Asia HIV Observational Database. Impact of Gender on Long-Term Treatment Outcomes of Highly Active Antiretroviral Therapy (HAART) in the TREAT Asia HIV Observational Database. AIDS Patient Care STDS. 2015 May;29(5):229-31. doi: 10.1089/apc.2014.0232. Epub 2015 Mar 16.
  38. Avihingsanon A, Tongkobpetch S, Kerr SJ, Punyawudho B, Suphapeetiporn K, Gorowara M, Ruxrungtham K, Shotelersuk V. Pharmacogenetic testing can identify patients taking atazanavir at risk for hyperbilirubinemia. J Acquir Immune Defic Syndr. 2015 May 1;69(1):e36-7. doi: 10.1097/QAI.0000000000000540.
  39. Wilaisakditipakorn T, Vilaisaktipakorn P, Bunupuradah T, Puthanakit T. A slow progressor HIV-infected boy developing quadriplegia with evidence of Epstein-Barr virus associated smooth muscle tumour of the cervical spinal cord. BMJ Case Rep. 2015 Jun 29;2015. pii: bcr2015210133. doi: 10.1136/bcr-2015-210133.
  40. Aurpibul L, Bunupuradah T, Sophan S, Boettiger D, Wati DK, Nguyen LV, Saphonn V, Hansudewechakul R, Chokephaibulkit K, Lumbiganon P, Truong KH, Do VC, Kumarasamy N, Yusoff NK, Razali K, Kurniati N, Fong SM, Nallusamy R, Sohn AH; TREAT Asia Pediatric HIV Observational Database. Prevalence and incidence of liver dysfunction and assessment of biomarkers of liver disease in HIV-infected Asian children. Pediatr Infect Dis J. 2015 Jun;34(6):e153-8. doi: 10.1097/INF.0000000000000693.
  41. Sax PE, Wohl D, Yin MT, Post F, DeJesus E, Saag M, Pozniak A, Thompson M, Podzamczer D, Molina JM, Oka S, Koenig E, Trottier B, Andrade-Villanueva J, Crofoot G, Custodio JM, Plummer A, Zhong L, Cao H, Martin H, Callebaut C, Cheng AK, Fordyce MW, McCallister S; GS-US-292-0104/0111 Study Team. Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials. Lancet. 2015 Jun 27;385(9987):2606-15. doi: 10.1016/S0140-6736(15)60616-X. Epub 2015 Apr 15.
  42. Bunupuradah T, KiertiburanakulS, Avihingsanon A, Chetchotisakd P, Techapornroong M, Leerattanapetch N,Kantipong P, Bowonwatanuwong C, Banchongkit S, Klinbuayaem V, Mekviwattanawong S, Nimitvilai S, Jirajariyavej S, Prasithsirikul W, Munsakul W,  Bhakeecheep S, Chaivooth S,  Phanuphak P, Cooper DA, Apornpong T,  Kerr SJ, Emery S,  Ruxrungtham R on behalf of the LASA Study Group. Atazanavir/ritonavir 200/100 mg is non-inferior to atazanavir/ritonavir 300/100 mg in virologic suppressed HIV-infected Thai adults: a multicentre, randomized, open-label trial: LASA. Journal of the International AIDS Society. 2015 Jul.
  43. ENCORE1 Study Group, Carey D, Puls R, Amin J, Losso M, Phanupak P, Foulkes S, Mohapi L, Crabtree-Ramirez B, Jessen H, Kumar S, Winston A, Lee MP, Belloso W, Cooper DA, Emery S. Efficacy and safety of efavirenz 400 mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study. Lancet Infect Dis. 2015 Jul;15(7):793-802. doi: 10.1016/S1473-3099(15)70060-5. Epub 2015 Apr 12.
  44. Obach D, Yazdanpanah Y, Esmat G, Avihingsanon A, Dewedar S, Durier N, Attia A, Anwar WA, Cousien A, Tangkijvanich P, Eholié SP, Doss W, Mostafa A, Fontanet A, Mohamed MK, Deuffic-Burban S. How to optimize hepatitis C virus treatment impact on life years saved in resource-constrained countries. Hepatology. 2015 Jul;62(1):31-9. doi: 10.1002/hep.27691. Epub 2015 Feb 27.
  45. Ahn JY, Boettiger D, Law M, Kumarasamy N, Yunihastuti E, Chaiwarith R, Lee MP, Sim BL, Oka S, Wong W, Kamarulzaman A, Kantipong P, Phanuphak P, Ng OT, Kiertiburanakul S, Zhang F, Pujari S, Ditangco R, Ratanasuwan W, Merati TP, Saphonn V, Sohn AH, Choi JY; TREAT Asia HIV Observational Databases (TAHOD). Implementation and Operational Research: Effects of CD4 Monitoring Frequency on Clinical End Points in Clinically Stable HIV-Infected Patients With Viral Suppression. J Acquir Immune Defic Syndr. 2015 Jul 1;69(3):e85-92. doi: 10.1097/QAI.0000000000000634.
  46. Maartens G, Meintjes G. Lower-dose efavirenz: what is needed before implementation? Lancet Infect Dis. Lancet Infect Dis. 2015 Jul;15(7):749-51. doi: 10.1016/S1473-3099(15)70108-8. Epub 2015 Apr 12.
  47. Bunupuradah T, Punyahotra P, Cressey TR, Srimuan A, Thammajaruk N, Sophonphan J, Sriheara C, Burger DM, Puthanakit T, Ananworanich J on behalf of the HIV-NAT 167 study team. Plasma pharmacokinetics of once-daily Abacavir- and lamivudine-containing regimens and week 96 efficacy in HIV-infected Thai children. J Virus Erad. 2015 Jul 1;1(3):185-91.
  48. INSIGHT START Study Group, Lundgren JD, Babiker AG, Gordin F, Emery S, Grund B, Sharma S,Avihingsanon A, Cooper DA, Fätkenheuer G, Llibre JM, Molina JM, Munderi P, Schechter M, Wood R, Klingman KL, Collins S, Lane HC, Phillips AN, Neaton JD. Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection. N Engl J Med. 2015 Aug 27;373(9):795-807. doi: 10.1056/NEJMoa1506816. Epub 2015 Jul 20.
  49. Cressey TR, Avihingsanon A, Halue G, Leenasirimakul P, Sukrakanchana PO, Tawon Y, Jaisieng N, Jourdain G, Podany AT, Fletcher CV, Klinbuayaem V, Bowonwatanuwong C. Plasma and Intracellular Pharmacokinetics of Tenofovir Disoproxil Fumarate 300 mg Every 48 Hours vs 150 mg Once Daily in HIV-Infected Adults With Moderate Renal Function Impairment. Clin Infect Dis. 2015 Aug 15;61(4):633-9. doi: 10.1093/cid/civ346. Epub 2015 Apr 28.
  50. Jahanshad N, Couture MC, Prasitsuebsai W, Nir TM, Aurpibul L, Thompson PM, Pruksakaew K, Lerdlum S, Visrutaratna P, Catella S, Desai A, Kerr SJ, Puthanakit T, Paul R, Ananworanich J, Valcour VG; SEARCH 012 and the PREDICT Study Groups. Brain Imaging and Neurodevelopment in HIV-uninfected Thai Children Born to HIV-infected Mothers. Pediatr Infect Dis J. 2015 Sep;34(9):e211-6. doi: 10.1097/INF.0000000000000774.
  51. Bunupuradah T, Anugulruengkitt S, Jantarabenjakul W, Pitimahajanaka T, Thammasala S, Laopraynak N, Prasitsuebsai W, Puthanakit T, on behalf of study team. Efficacy and Safety of Hepatitis B Revaccination in HIV-infected Thai Children and Adolescents. Journal of Infectious Diseases and Antimicrobial Agents. 2015 Sep-Dec;32(3):113-118.
  52. Oyomopito RA, Chen YJ, Sungkanuparph S, Kantor R, Merati T, Yam WC, Sirisanthana T, Li PC, Kantipong P, Phanuphak P, Lee CK, Kamarulzaman A, Ditangco R, Huang SW, Sohn AH, Law M, Chen YM. Risk group characteristics and viral transmission clusters in South-East Asian patients infected with human immunodeficiency virus-1 (HIV-1) circulating recombinant form (CRF) 01_AE and subtype B. Kaohsiung J Med Sci. 2015 Sep;31(9):445-53. doi: 10.1016/j.kjms.2015.07.002. Epub 2015 Aug 21.
  53. Tee KK, Kantor R, Sungkanuparph S, Takebe Y, Li P, Ditangco R, Phanuphak P, Sirisanthana T, Sim B, Ratanasuwan W, Kantipong P, Kamarulzaman A. Transmission Networks of HIV-1 Among Men Who Have Sex With Men in East and Southeast Asia. J Acquir Immune Defic Syndr. 2015 Sep 1;70(1):e28-30. doi: 10.1097/QAI.0000000000000614.
  54. Bunupuradah T, Thongpunchang B, Nipathakosol P, Ohata J, Sethaputra C, Saisaengjan C, Hansudewechakul R, Pancharoen C and Puthanakit T. Barriers and best practices of transitioning perinatally HIV-infected adolescents to adult care in Asia-Pacific. J Virus Erad. 2015 Oct 1;1(4):284-5.
  55. Dickinson L, Amin J, Else L, Boffito M, Egan D, Owen A, Khoo S, Back D, Orrell C, Clarke A, Losso M, Phanuphak P, Carey D, Cooper DA, Emery S; R Puls2, on behalf of the ENCORE1 Study Group. Pharmacokinetic and Pharmacodynamic Comparison of Once-Daily Efavirenz (400 mg vs. 600 mg) in Treatment-Naïve HIV-Infected Patients: Results of the ENCORE1 Study. Clin Pharmacol Ther. 2015 Oct;98(4):406-16. doi: 10.1002/cpt.156. Epub 2015 Jul 14.
  56. Putcharoen O, Do T, Avihingsanon A, Ruxrungtham K. Rationale and clinical utility of the darunavir-cobicistat combination in the treatment of HIV/AIDS. Drug Des Devel Ther. 2015 Oct 23;9:5763-9. doi: 10.2147/DDDT.S63989. eCollection 2015.
  57. Prasitsuebsai W, Kerr SJ, Truong KH, Ananworanich J, Do VC, Nguyen LV, Kurniati N, Kosalaraksa P, Sudjaritruk T, Chokephaibulkit K, Thammajaruk N, Singtoroj T, Teeraananchai S, Horng H, Bacchetti P, Gandhi M, Sohn AH. Using Lopinavir Concentrations in Hair Samples to Assess Treatment Outcomes on Second-Line Regimens Among Asian Children. AIDS Res Hum Retroviruses. 2015 Oct;31(10):1009-14. doi: 10.1089/AID.2015.0111. Epub 2015 Aug 26.
  58. Valcour VG, Spudich SS, Sailasuta N, Phanuphak N, Lerdlum S, Fletcher JL, Kroon ED, Jagodzinski LL, Allen IE, Adams CL, Prueksakaew P, Slike BM, Hellmuth JM, Kim JH, Ananworanich J; SEARCH 010/RV 254 Study Group. Neurological Response to cART vs. cART plus Integrase Inhibitor and CCR5 Antagonist Initiated during Acute HIV. PLoS One. 2015 Nov 10;10(11):e0142600. doi: 10.1371/journal.pone.0142600. eCollection 2015.
  59. Paediatric European Network for Treatment of AIDS (PENTA). Once vs. twice-daily lopinavir/ritonavir in HIV-1-infected children. AIDS. 2015 Nov 28;29(18):2447-57. doi: 10.1097/QAD.0000000000000862.
  60. Punyawudho B, Thammajaruk N, Thongpeang P, Matthews G, Lewin SR, Burger D, Ruxrungtham K, Avihingsanon A. Population pharmacokinetics of tenofovir in HIV/HBV co-infected patients. Int J Clin Pharmacol Ther. 2015 Nov;53(11):947-54. doi: 10.5414/CP202386.
  61. Tulloch O, Taegtmeyer M, Ananworanich J, Chasombat S, Kosalaraksa P, Theobald S. What can volunteer co-providers contribute to health systems? The role of people living with HIV in the Thai paediatric HIV programme. Soc Sci Med. 2015 Nov;145:184-92. doi: 10.1016/j.socscimed.2014.09.017. Epub 2014 Sep 10.
  62. Bunupuradah T, Matsuoka K, Imahashi M, Iwatani Y, Ananworanich J, Puthanakit T, Saphonn V, Aurpibul L, Sophonphan J, Yagi T, Phanuphak P,  Sugiura W. APOBEC3G genotypes and proviral DNA hypermutations on HIV/AIDS disease progression in Thai and Cambodian children. Future Virology. 2015 Dec. DOI: 10.2217/fvl.15.101.
  63. Pavia-Ruz N, Rossouw M, Sáez-Llorens X, Bunupuradah T, Taylor M, Yang R, Sevinsky H, Krystal M, Lataillade M, Seekins D, Biguenet S. Efavirenz Capsule Sprinkle and Liquid Formulations with Didanosine and Emtricitabine in HIV-1-Infected Infants and Children 3 Months to 6 Years of Age: Study AI266-922. Pediatr Infect Dis J. 2015 Dec;34(12):1355-60. doi: 10.1097/INF.0000000000000913.
  64. Kore I, Ananworanich J, Valcour V, Fletcher JL, Chalermchai T, Paul R, Reynolds J, Tipsuk S, Ubolyam S, Rattanamanee S, Jagodzinski L, Kim J, Spudich S; RV254/SEARCH 010 Study Group. Neuropsychological Impairment in Acute HIV and the Effect of Immediate Antiretroviral Therapy. J Acquir Immune Defic Syndr. 2015 Dec 1;70(4):393-9. doi: 10.1097/QAI.0000000000000746.
  65. Kancheva Landolt N, Bunupuradah T, Achalapong J, Kosalaraksa P, Petdachai W, Ngampiyaskul C, Auchieng C, Ananworanich J, Boonyanurak P. Premenstrual Disorders Among Perinatally HIV-Infected Adolescents. J Acquir Immune Defic Syndr. 2015 Dec 1;70(4):e150-3. doi: 10.1097/QAI.0000000000000762.
  66. Rungtivasuwan K, Avihingsanon A, Thammajaruk N, Mitruk S, Burger DM, Ruxrungtham K, Punyawudho B, Pengsuparp T. Influence of ABCC2 and ABCC4 polymorphisms on tenofovir plasma concentrations in Thai HIV-infected patients. Antimicrob Agents Chemother. 2015;59(6):3240-5. doi: 10.1128/AAC.04930-14. Epub 2015 Mar 23.
  67. Avihingsanon A, Apornpong T, Kerr SJ, Make-a-nantawat W, Thammajaruk N,Phonphithak S, Ramautarsing RA, Clarke A, Phanuphak P, Burger DM, Ruxrungtham Rand HIV-NAT 006 study team. Low Dose Ritonavir-Boosted Atazanavir (200/100 mg) maintained high virological efficacy up to 4 years in treatment-experienced HIV-1 Infected Adults: A prospective cohort study from Asia. J AIDS Clin Res. 2015;6:460.
  68. Kancheva Landolt N, Phanuphak N, Khongpetch C, Kriengsinyot R, Teeratakulpisarn S, Ubolyam S, Kerr S, Pinyakorn S, Chaithongwongwatthana S, Phanuphak P, Avihingsanon A, Ananworanich J. Low uptake of HIV testing and no HIV positivity in stable serodiscordant heterosexual partners of long-term treated HIV-infected Thais. AIDS Care. 2015;27(5):587-94. doi: 10.1080/09540121.2014.989485. Epub 2014 Dec 15.
  69. Avihingsanon A, Sophonphan J, Thammajaruk N, Chaihong P, Burger D, Cressey TR, Ramautarsing RA, Praditornsilpa K, Avihingsanon Y, Ruxrungtham K and HIV-NAT 114 study team. Plasma Tenofovir Concentrations and Proximal Tubular Dysfunction in HIV-Infected Adults Receiving Tenofovir in Thailand. J AIDS Clin Res. 2015;6:477. doi:10.4172/2155-6113.1000477.
  70. Ananworanich J, Kerr SJ, Jaimulwong T, Vibol U, Hansudewechakul R, Kosalaraksa P, Ngampiyaskul C, Kanjanavanit S, Wongsawat J, Luesomboon W, Apornpong T, Soulas C, Paul R, Ruxrungtham K, Puthanakit T. Soluble CD163 and monocyte populations in response to antiretroviral therapy and in relationship with neuropsychological testing among HIV-infected children. J Virus Erad. 2015;1(3):196-202. Epub 2015 Jun 30.
  71. Thong VD, Akkarathamrongsin S, Avihingsanon A, Theamboonlers A, Poovorawan Y, Tangkijvanich P. The correlation between hepatitis C core antigen and hepatitis C virus RNA levels with respect to human immunodeficiency virus status, hepatitis C virus genotype and interferon-lambda-4 polymorphism. Intervirology. 2015;58(2):73-9. doi: 10.1159/000370070. Epub 2015 Feb 13.